

Roy A Pleasants

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6711863/publications.pdf>

Version: 2024-02-01

45
papers

826
citations

566801

15
h-index

500791

28
g-index

45
all docs

45
docs citations

45
times ranked

1184
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2022, Volume 17, 79-92.	0.9	8
2	Interstitial lung disease in a veterans affairs regional network; a retrospective cohort study. PLoS ONE, 2021, 16, e0247316.	1.1	7
3	Effect of OM-85 BV on reducing bronchiectasis exacerbation in Chinese patients: the iPROBE study. Journal of Thoracic Disease, 2021, 13, 1641-1651.	0.6	3
4	A population-based estimate of the health care burden of obstructive sleep apnea using a STOP-BAG questionnaire in South Carolina. Journal of Clinical Sleep Medicine, 2021, 17, 367-374.	1.4	10
5	Relationship between alpha-1 antitrypsin deficiency and obstructive sleep apnea. Sleep and Breathing, 2021, 25, 2091-2097.	0.9	1
6	Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective. Pulmonary Therapy, 2021, 7, 345-376.	1.1	37
7	User-life of ICS/LABA inhaler devices should be considered when prescribed as relievers. European Respiratory Journal, 2021, 57, 2003921.	3.1	0
8	INHALATION PARAMETERS IN PATIENTS WITH ASTHMA USING ALBUTEROL ELECTRONIC MULTI-DOSE DRY POWDER INHALER. Chest, 2020, 158, A39-A40.	0.4	0
9	REMOTELY RECORDED PEAK INHALATION FLOW PATTERNS AMONG PATIENTS WITH COPD USING PROAIR DIGIHALER FOR RESCUE MEDICATION. Chest, 2020, 158, A1708-A1710.	0.4	2
10	EFFECT OF ACUTE BRONCHODILATION ON PEAK INSPIRATORY FLOW IN PATIENTS WITH STABLE COPD. Chest, 2020, 158, A2626-A2627.	0.4	1
11	Both Duration and Pack-Years of Tobacco Smoking Should Be Used for Clinical Practice and Research. Annals of the American Thoracic Society, 2020, 17, 804-806.	1.5	25
12	Procalcitonin for Antibiotic Prescription in Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective. Pulmonary Therapy, 2020, 6, 201-214.	1.1	11
13	A Systematic Review and Meta-Analysis of Sputum Purulence to Predict Bacterial Infection in COPD Exacerbations. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 311-317.	0.7	13
14	Medication Safety in Chronic Lung Disease with Cardiac Comorbidity. Respiratory Medicine, 2020, , 161-212.	0.1	0
15	Management of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2019, 53, 1238-1248.	0.9	27
16	Optimizing Drug Therapies in Patients with COPD in the US Nursing Home Setting. Drugs and Aging, 2019, 36, 733-745.	1.3	6
17	<p>Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD<p>. International Journal of COPD, 2019, Volume 14, 585-595.	0.9	48
18	PATTERNS OF RESCUE MEDICATION USAGE IN ASTHMA PATIENTS RECORDED BY THE ELECTRONIC PROAIR DIGIHALER. Chest, 2019, 156, A215-A216.	0.4	3

#	ARTICLE	IF	CITATIONS
19	TARGETING OSA USING STATE-BASED SURVEILLANCE. <i>Chest</i> , 2019, 156, A950-A951.	0.4	0
20	Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease. <i>Annals of Pharmacotherapy</i> , 2019, 53, 285-293.	0.9	3
21	A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study. <i>Iproceedings</i> , 2019, 5, e15173.	0.1	1
22	Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma. <i>Clinical Drug Investigation</i> , 2018, 38, 463-473.	1.1	7
23	Nebulized Corticosteroids in the Treatment of COPD Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective. <i>Respiratory Care</i> , 2018, 63, 1302-1310.	0.8	14
24	Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases. <i>Respiratory Care</i> , 2018, 63, 671-689.	0.8	15
25	Aerosol Delivery Devices for Obstructive Lung Diseases. <i>Respiratory Care</i> , 2018, 63, 708-733.	0.8	59
26	Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data. <i>European Journal of Pediatrics</i> , 2018, 177, 145-154.	1.3	25
27	Dry Powder Inhalers and Humidity: Another Factor to Consider to Ensure Adequate Lung Delivery. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1602-1602.	1.5	7
28	Defining and targeting health disparities in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2016, Volume 11, 2475-2496.	0.9	114
29	Methods for using microblogs for health communication with a pharmacist-based account. <i>Patient Education and Counseling</i> , 2016, 99, 1432-1437.	1.0	0
30	Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. <i>Drugs</i> , 2016, 76, 343-361.	4.9	22
31	Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD. <i>International Journal of COPD</i> , 2015, 10, 775.	0.9	2
32	Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history. <i>International Journal of COPD</i> , 2015, 10, 1409.	0.9	107
33	Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 680-9.	0.7	7
34	Chronic Obstructive Pulmonary Disease and Asthma—Patient Characteristics and Health Impairment. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 11, 131023065803008.	0.7	67
35	The prevalence, characteristics, and impact of chronic obstructive pulmonary disease in North Carolina. <i>North Carolina Medical Journal</i> , 2013, 74, 376-83.	0.1	4
36	Mortality from Chronic Obstructive Pulmonary Disease Among Adults Aged 25 Years or Older in North Carolina. <i>Southern Medical Journal</i> , 2011, 104, 20-23.	0.3	4

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life and chronic obstructive pulmonary disease in North Carolina. North American Journal of Medical Sciences, 2010, 2, 60-5.	1.7	17
38	Allergic Reactions to Parenteral Beta-lactam Antibiotics in Patients With Cystic Fibrosis. Chest, 1994, 106, 1124-1128.	0.4	83
39	Arthropathy Secondary to Ciprofloxacin in an Adult Cystic Fibrosis Patient. Annals of Pharmacotherapy, 1993, 27, 302-303.	0.9	21
40	Compatibility of Ceftazidime and Aminophylline Admixtures for Different Methods of Intravenous Infusion. Annals of Pharmacotherapy, 1992, 26, 1221-1226.	0.9	8
41	Reassessment of Cross-Reactivity of Spironolactone Metabolites with Four Digoxin Immunoassays. Therapeutic Drug Monitoring, 1989, 11, 200-204.	1.0	30
42	Tobramycin Administration and Blood Sampling through a Dual-Lumen Peripheral Intravenous Catheter. DICP: the Annals of Pharmacotherapy, 1989, 23, 460-463.	0.2	3
43	Determination of Clearance from a Trough Serum Concentration at Steady State. Drug Intelligence & Clinical Pharmacy, 1987, 21, 69-70.	0.4	0
44	Lack of Apparent Effect of Assay Methodology on the Pharmacokinetics of Digoxin. Therapeutic Drug Monitoring, 1987, 9, 416-421.	1.0	2
45	Estimation of the Steady-State Volume of Distribution for Digoxin: A Comparison of Model-Independent Methods with a Two-Compartment Model in Healthy Volunteers. Drug Intelligence & Clinical Pharmacy, 1985, 19, 837-839.	0.4	2